Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity. Reply

N Engl J Med. 2023 Dec 21;389(25):2398-2399. doi: 10.1056/NEJMc2312296.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Glucagon-Like Peptides / therapeutic use
  • Heart Failure* / drug therapy
  • Humans
  • Obesity / complications
  • Stroke Volume

Substances

  • semaglutide
  • Glucagon-Like Peptides